{
    "EU-1-21-1541_h_a_dec_0.pdf": [
        "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/dec_154987_en.pdf",
        "2022-03-24 00:00:00",
        "2022-11-24 22:47:01.101162"
    ],
    "EU-1-21-1541_h_a_anx_0.pdf": [
        "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/anx_154987_en.pdf",
        "2022-03-24 00:00:00",
        "2022-11-24 22:47:01.325503"
    ],
    "EU-1-21-1541_h_dec_0.pdf": [
        "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/dec_154987_en.pdf",
        "2022-03-24 00:00:00",
        "2022-11-25 15:54:46.560108"
    ],
    "EU-1-21-1541_h_anx_0.pdf": [
        "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/anx_154987_en.pdf",
        "2022-03-24 00:00:00",
        "2022-11-25 15:54:46.722181"
    ],
    "EU-1-21-1541_h_public-assessment-report.pdf": [
        "https://www.ema.europa.eu/documents/assessment-report/dasatinib-accordpharma-epar-public-assessment-report_en.pdf",
        "2022-11-25 15:54:46.991949",
        "2022-11-25 15:54:46.991949"
    ]
}